Prof. Patrik Brundin leads the Center for Neurodegenerative Science at Van Andel Research Institute where his research team is focused on experimental models and novel therapies in Parkinson’s disease. Prof. Brundin is one of the most cited scientists in neurodegenerative diseases, with a focus on Parkinson’s, and has received numerous awards for his work. He is the co-editor-in-chief of the Journal of Parkinson’s Disease and is a consultant for several biotech and pharmaceutical companies; he also chairs our Linked Clinical Trials committee. Research in Patrik Brundin’s laboratory focuses on pathogenetic mechanisms and pharmacological treatment in cell and animal models of Parkinson’s disease. The group’s mission is to understand neurodegenerative diseases and develop new therapies that are of benefit to patients and their caregivers. 

Read the full interview.

Thanks to Ben Stecher - author 'Tomorrow Edition'